Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short-term Investments (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Short-term Investments readings, the most recent being $1.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 15.51% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, up 15.51%, and an annual FY2025 reading of $1.5 million, up 15.51% over the prior year.
  • Short-term Investments hit $1.5 million in Q4 2025 for Apellis Pharmaceuticals, up from $1.4 million in the prior quarter.
  • The five-year high for Short-term Investments was $248.3 million in Q2 2022, with the low at $1.1 million in Q2 2023.
  • Median Short-term Investments over the past 5 years was $1.4 million (2025), compared with a mean of $30.1 million.
  • The sharpest move saw Short-term Investments plummeted 99.69% in 2021, then surged 15419.19% in 2022.
  • Year by year, Short-term Investments stood at $60.4 million in 2021, then plummeted by 97.89% to $1.3 million in 2022, then fell by 12.49% to $1.1 million in 2023, then rose by 18.67% to $1.3 million in 2024, then increased by 15.51% to $1.5 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $1.5 million, $1.4 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.